Long-acting parenteral nanoformulated antiretroviral therapy: interest and attitudes of HIV-infected patients

被引：89

作者：

Williams, Jennifer ^{[1
]}

Sayles, Harlan R. ^{[2
]}

Meza, Jane L. ^{[2
]}

Sayre, Patrick ^{[3
]}

Sandkovsky, Uriel ^{[1
]}

Gendelman, Howard E. ^{[1
,4
]}

Flexner, Charles ^{[3
]}

Swindells, Susan ^{[1
]}

机构：

[1] Univ Nebraska Med Ctr, Dept Internal Med, Omaha, NE 68198 USA

[2] Univ Nebraska Med Ctr, Dept Biostat, Omaha, NE 68198 USA

[3] Johns Hopkins Univ, Div Clin Pharmacol, Baltimore, MD 21287 USA

[4] Univ Nebraska Med Ctr, Dept Pharmacol & Expt Neurosci, Omaha, NE 68198 USA

来源：

NANOMEDICINE | 2013年 / 8卷 / 11期

关键词：

AIDS; antiretroviral therapy; HIV; intravenous drug abuse; nanoformulated antiretroviral therapy; nonadherence; substance abuse; DRUG-RESISTANCE; NANOMEDICINE; ADHERENCE; MICE;

D O I：

10.2217/nnm.12.214

中图分类号：

Q81 [生物工程学（生物技术）]; Q93 [微生物学];

学科分类号：

071005 ; 0836 ; 090102 ; 100705 ;

摘要：

Aim: To gauge patient interest in receiving long-acting injectable nanoformulated antiretroviral therapy. Methods: Four hundred adult HIV-infected patients currently prescribed antiretroviral therapy were surveyed. (2) tests were used for comparisons of interest across groups. Results: Respondents were 68% male and 53% African-American, with a mean age of 47 years. Overall, 73% of patients indicated that they would definitely or probably try injectable nanoformulated antiretroviral therapy; 61% with weekly dosing; 72% every 2 weekly; and 84% monthly. In total, 48% indicated that they were very concerned about the possible side effects and 35% were very concerned about needle use. Conclusion: The majority of respondents indicated that they definitely or probably would try parenteral nanoformulated antiretroviral therapy. Original submitted 24 May 2012; Revised submitted 2 November 2012; Published online 23 April 2013

引用

页码：1807 / 1813

页数：7

共 19 条

[1] Treatment of medical, psychiatric, and substance-use comorbidities in people infected with HIV who use drugs [J].

Altice, Frederick L. ;

Kamarulzaman, Adeeba ;

Soriano, Vincent V. ;

Schechter, Mauro ;

Friedland, Gerald H. .

LANCET, 2010, 376 (9738) :367-387

[2]

[Anonymous], 2009, 2 COMM COMM COUNC EU

[3] Development of a long-acting injectable formulation with nanoparticles of rilpivirine (TMC278) for HIV treatment [J].

Baert, Lieven ;

van 't Klooster, Gerben ;

Dries, Willy ;

Francois, Marc ;

Wouters, Alfons ;

Basstanie, Esther ;

Iterbeke, Koen ;

Stappers, Fred ;

Stevens, Paul ;

Schueller, Laurent ;

Van Remoortere, Pieter ;

Kraus, Guenter ;

Wigerinck, Piet ;

Rosier, Jan .

EUROPEAN JOURNAL OF PHARMACEUTICS AND BIOPHARMACEUTICS, 2009, 72 (03) :502-508

[4]

Bainbridge WS, 2002, J NANOPART RES, V4, P561

[5] Comparative manufacture and cell-based delivery of antiretroviral nanoformulations [J].

Balkundi, Shantanu ;

Nowacek, Ari S. ;

Veerubhotla, Ram S. ;

Chen, Han ;

Martinez-Skinner, Andrea ;

Roy, Upal ;

Mosley, R. Lee ;

Kanmogne, Georgette ;

Liu, Xinming ;

Kabanov, Alexander V. ;

Bronich, Tatiana ;

McMillan, JoEllyn ;

Gendelman, Howard E. .

INTERNATIONAL JOURNAL OF NANOMEDICINE, 2011, 6 :3393-3404

[6] Public optimism towards nanomedicine [J].

Bottini, Massimo ;

Rosato, Nicola ;

Gloria, Fulvia ;

Adanti, Sara ;

Corradino, Nunziella ;

Bergamaschi, Antonio ;

Magrini, Andrea .

INTERNATIONAL JOURNAL OF NANOMEDICINE, 2011, 6 :3473-+

[7] Self-reported adherence to antiretroviral medications among participants in HIV clinical trials: the AACTG Adherence Instruments [J].

Chesney, MA ;

Ickovics, JR ;

Chambers, DB ;

Gifford, AL ;

Neidig, J ;

Zwickl, B ;

Wu, AW .

AIDS CARE-PSYCHOLOGICAL AND SOCIO-MEDICAL ASPECTS OF AIDS/HIV, 2000, 12 (03) :255-266

[8] Long-acting nanoformulated antiretroviral therapy elicits potent antiretroviral and neuroprotective responses in HIV-1-infected humanized mice [J].

Dash, Prasanta K. ;

Gendelman, Howard E. ;

Roy, Upal ;

Balkundi, Shantanu ;

Alnouti, Yazen ;

Mosley, Rodney L. ;

Gelbard, Harris A. ;

McMillan, JoEllyn ;

Gorantla, Santhi ;

Poluektova, Larisa Y. .

AIDS, 2012, 26 (17) :2135-2144

[9] Nanoparticle-based combination therapy toward overcoming drug resistance in cancer [J].

Hu, Che-Ming Jack ;

Zhang, Liangfang .

BIOCHEMICAL PHARMACOLOGY, 2012, 83 (08) :1104-1111

[10]

Jackson Akil EL, 2012, 19 C RETR OPP INF SE

← 1 2 →